🔗 Share this article Recent Antimicrobials Celebrated as a 'Major Shift' in Combating Drug-Resistant Gonorrhea The first new treatments for gonorrhoea in a generation are being hailed as a "significant breakthrough" in the fight against drug-resistant strains of the pathogen, according to researchers. An International Health Concern Gonorrhoea infections are on the rise around the world, with estimates suggesting in excess of 82 million infections annually. Particularly high rates are seen in the African continent and countries within the World Health Organization's Western Pacific region, which includes China and Mongolia to New Zealand. In England, cases have reached a historical peak, while infection numbers across Europe in 2023 were significantly elevated compared to the rates from 2014. “The approval of new treatments for gonorrhoea is an significant and necessary advancement in the context of growing infection rates, increasing antimicrobial resistance and the highly restricted treatment choices at this time.” Public health authorities are particularly alarmed about the rise in treatment-resistant strains. The World Health Organization has listed it as a "high-priority threat". Ongoing monitoring revealed that resistance to key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024. Two New Treatment Options Secure Approval Zoliflodacin, marketed under the name Nuzolvence, was approved by the American regulatory agency in recent days for use against gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Researchers believe that specific application of this new drug will help hinder the emergence of superbugs. Gepotidacin, created by the pharmaceutical company GSK, gained clearance in close succession. This treatment, which is also used to treat UTIs, was proven in research to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria. An Innovative Approach to Creation Zoliflodacin stemmed from a unique collaborative effort for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to see it through. “This approval represents a huge turning point in the therapy of multidrug-resistant gonorrhoea, which previously has been evolving faster than antibiotic development.” Clinical Trial Results and Global Access According to results published in a major medical journal, the new drug eradicated over nine in ten of cases of the STI. This puts it on an comparable level with the current standard treatment, which combines two antibiotics. The trial involved nearly 1,000 participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US. Under the terms of its collaboration, the non-profit has the ability to register and commercialise the drug in a wide range of regions with limited resources. Clinicians directly involved have shared positive views. Having a single-dose, oral treatment of this kind is seen as a "game-changer" for public health efforts. This is viewed as crucial to reduce the burden of the infection for individuals and to prevent the spread of highly drug-resistant gonorrhoea globally.